The trademark LEXTEMY was filed by Mylan Institutional Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on May 18, 2020, and received one opposition filed on August 12, 2020 by SOFAR S.P.A. on Likelihood of confusion. the opponent was represented by Benedetto, Marco and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued August 12, 2020
The application was filed in English, and English was also language of all opposition proceedings (German was selected as the second language).
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceuticals (except for the treatment of gastrointestinal disorders, of ulcerative colitis, of bowel disease and/or of Crohn’s disease)
Pharmaceutical and medical preparations (except for the treatment of gastrointestinal disorders, of ulcerative colitis, of bowel disease and/or of Crohn’s disease)
Pharmaceutical preparations for the treatment of cancer
Pharmaceutical preparations for the treatment of Non Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Pharmaceutical preparations for the treatment of rheumatoid arthritis, chronic plaque psoriasis, ankylosing spondylitis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis.